Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Journal of Pulmonology and Respiratory Diseases received 244 citations as per Google Scholar report
Infliximab is used for treating the inflammation of Crohn's disease, rheumatoid arthritis, psoriasis, ankylosing spondylitis, and psoriatic arthritis. Infliximab is an antibody administered intravenously that is used for treating several chronic inflammatory diseases. Infliximab works by blocking the effects of tumor necrosis factor alpha (TNF alpha), a substance made by cells of the body which has an important role in promoting inflammation. Infliximab does not cure Crohn's disease, psoriatic arthritis, or rheumatoid arthritis. Infliximab can retard the destruction of joints by rheumatoid arthritis.
Related Journals of Infliximab
Journal of Tumor Research Open Access Journal, Journal of Immunobiology, Journal of Immunological Techniques & Infectious Diseases, Journal of Immunooncology, Journal of Molecular Immunology, Journal of Mucosal Immunology Research